386 related articles for article (PubMed ID: 27928945)
1. JAK/STAT Signal Transduction: Promising Attractive Targets for Immune, Inflammatory and Hematopoietic Diseases.
Gao Q; Liang X; Shaikh AS; Zang J; Xu W; Zhang Y
Curr Drug Targets; 2018; 19(5):487-500. PubMed ID: 27928945
[TBL] [Abstract][Full Text] [Related]
2. The role of JAK/STAT signaling pathway and its inhibitors in diseases.
Xin P; Xu X; Deng C; Liu S; Wang Y; Zhou X; Ma H; Wei D; Sun S
Int Immunopharmacol; 2020 Mar; 80():106210. PubMed ID: 31972425
[TBL] [Abstract][Full Text] [Related]
3. The arrival of JAK inhibitors: advancing the treatment of immune and hematologic disorders.
Furumoto Y; Gadina M
BioDrugs; 2013 Oct; 27(5):431-8. PubMed ID: 23743669
[TBL] [Abstract][Full Text] [Related]
4. JAK-STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects.
Banerjee S; Biehl A; Gadina M; Hasni S; Schwartz DM
Drugs; 2017 Apr; 77(5):521-546. PubMed ID: 28255960
[TBL] [Abstract][Full Text] [Related]
5. Molecular dissection of Janus kinases as drug targets for inflammatory diseases.
Kwon S
Front Immunol; 2022; 13():1075192. PubMed ID: 36569926
[TBL] [Abstract][Full Text] [Related]
6. Pathogenic and Therapeutic Relevance of JAK/STAT Signaling in Systemic Lupus Erythematosus: Integration of Distinct Inflammatory Pathways and the Prospect of Their Inhibition with an Oral Agent.
Alunno A; Padjen I; Fanouriakis A; Boumpas DT
Cells; 2019 Aug; 8(8):. PubMed ID: 31443172
[TBL] [Abstract][Full Text] [Related]
7. Development of JAK inhibitors for the treatment of immune-mediated diseases: kinase-targeted inhibitors and pseudokinase-targeted inhibitors.
Kim HO
Arch Pharm Res; 2020 Nov; 43(11):1173-1186. PubMed ID: 33161563
[TBL] [Abstract][Full Text] [Related]
8. Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases.
Clark JD; Flanagan ME; Telliez JB
J Med Chem; 2014 Jun; 57(12):5023-38. PubMed ID: 24417533
[TBL] [Abstract][Full Text] [Related]
9. Involvement of JAK/STAT signaling in the pathogenesis of inflammatory bowel disease.
Coskun M; Salem M; Pedersen J; Nielsen OH
Pharmacol Res; 2013 Oct; 76():1-8. PubMed ID: 23827161
[TBL] [Abstract][Full Text] [Related]
10. JAK kinase targeting in hematologic malignancies: a sinuous pathway from identification of genetic alterations towards clinical indications.
Springuel L; Renauld JC; Knoops L
Haematologica; 2015 Oct; 100(10):1240-53. PubMed ID: 26432382
[TBL] [Abstract][Full Text] [Related]
11. Targeting JAK/STAT signalling in inflammatory skin diseases with small molecule inhibitors.
Welsch K; Holstein J; Laurence A; Ghoreschi K
Eur J Immunol; 2017 Jul; 47(7):1096-1107. PubMed ID: 28555727
[TBL] [Abstract][Full Text] [Related]
12. Defining the role of the JAK-STAT pathway in head and neck and thoracic malignancies: implications for future therapeutic approaches.
Lai SY; Johnson FM
Drug Resist Updat; 2010 Jun; 13(3):67-78. PubMed ID: 20471303
[TBL] [Abstract][Full Text] [Related]
13. JAK-STAT inhibitors: Immersing therapeutic approach for management of rheumatoid arthritis.
Singh S; Singh S
Int Immunopharmacol; 2020 Sep; 86():106731. PubMed ID: 32590315
[TBL] [Abstract][Full Text] [Related]
14. JAK/STAT as a Potential Therapeutic Target for Osteolytic Diseases.
Godoi MA; Camilli AC; Gonzales KGA; Costa VB; Papathanasiou E; Leite FRM; Guimarães-Stabili MR
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373437
[TBL] [Abstract][Full Text] [Related]
15. Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases.
Roskoski R
Pharmacol Res; 2016 Sep; 111():784-803. PubMed ID: 27473820
[TBL] [Abstract][Full Text] [Related]
16. The involvement of JAK/STAT signaling pathway in the treatment of Parkinson's disease.
Lashgari NA; Roudsari NM; Momtaz S; Sathyapalan T; Abdolghaffari AH; Sahebkar A
J Neuroimmunol; 2021 Dec; 361():577758. PubMed ID: 34739911
[TBL] [Abstract][Full Text] [Related]
17. Advances in the Development of Janus Kinase Inhibitors in Inflammatory Bowel Disease: Future Prospects.
Flamant M; Rigaill J; Paul S; Roblin X
Drugs; 2017 Jul; 77(10):1057-1068. PubMed ID: 28523588
[TBL] [Abstract][Full Text] [Related]
18. Cytokine receptor signaling through the Jak-Stat-Socs pathway in disease.
O'Sullivan LA; Liongue C; Lewis RS; Stephenson SE; Ward AC
Mol Immunol; 2007 Apr; 44(10):2497-506. PubMed ID: 17208301
[TBL] [Abstract][Full Text] [Related]
19. Targeting Janus Kinases and Signal Transducer and Activator of Transcription 3 to Treat Inflammation, Fibrosis, and Cancer: Rationale, Progress, and Caution.
Bharadwaj U; Kasembeli MM; Robinson P; Tweardy DJ
Pharmacol Rev; 2020 Apr; 72(2):486-526. PubMed ID: 32198236
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic potential of JAK/STAT pathway modulation in mood disorders.
Shariq AS; Brietzke E; Rosenblat JD; Pan Z; Rong C; Ragguett RM; Park C; McIntyre RS
Rev Neurosci; 2018 Dec; 30(1):1-7. PubMed ID: 29902157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
